A therosclerosis is the main underlying pathology of cardiovascular disease, which accounts for the majority of deaths in developed nations.
A therosclerosis is the main underlying pathology of cardiovascular disease, which accounts for the majority of deaths in developed nations. 1 Myeloid lineage cells are critical mediators in the development of atherosclerosis and account for the majority of a lesion's cellular bulk. 2 Within the atherosclerotic lesion, macrophages phagocytose modified lipid particles becoming lipid engorged foam cells. Foam cells exacerbate disease progression through the secretion of proinflammatory cytokines and growth factors. In advanced lesions, foam cells undergo apoptosis leading to the formation of a lipid-rich, acellular, and highly thrombotic necrotic core. The underlying molecular mechanisms that regulate myeloid cell behavior during atherosclerosis remain poorly defined.
Increasing evidence suggests that myeloid cell subpopulations are heterogeneous and have distinctive phenotypes that play unique roles in disease states. Macrophages are often broadly classified as having a classical (M1) or an alternative (M2) phenotype. M1 macrophages, elicited by toll-like receptor or interferon-γ receptor stimulation, are the most prominent macrophages at sites of inflammation and exacerbate the inflammatory response through the secretion of proinflammatory cytokines and chemoatractants. 3, 4 M1 macrophages promote atherosclerotic lesion development and complexity. [5] [6] [7] M2 macrophages patrol tissue, perform reparative and immunoregulatory functions, efferocytose debris, and are antiatherogenic. 3, 4, 8 Other macrophage subtypes have been identified in atherosclerotic lesions, including M4, Mox, and Mhem; however, their roles are less well characterized. 3, 5, 9, 10 Our understanding of the cellular signaling networks that regulate macrophage polarization in the context of atherosclerosis and the relative contribution of each phenotype to the progression and development of atherosclerosis is limited.
Glycogen synthase kinase (GSK)-3 α and β are homologous serine/threonine kinases encoded by separate genes.
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May 2015 unknown function. Both GSK3α and GSK3β are ubiquitously expressed although expression levels vary greatly from tissue to tissue. GSK3α/β is found in the cytoplasm, endoplasmic reticulum, and nucleus of most cells. 11 Originally described as a regulator of glycogen synthase and β-catenin, GSK3α/β is now recognized to be a target of several signaling networks, including insulin/PI3K (phosphoinositide 3-kinase)/ AKT (protein kinase B), MAPKs (mitogen-activated protein kinase), and endoplasmic reticulum stress. 11, 12 Although GSK3α and GSK3β share several common substrates, they are not redundant and seem to have distinct functions. [13] [14] [15] Wholebody GSK3α-deficient mice are viable and develop normally, whereas GSK3β deletion is embryonically lethal. [16] [17] [18] [19] Recent evidence has suggested a role of GSK3α/β in atherosclerosis. In mouse models, pharmacological inhibition of GSK3α/β or whole-body GSK3α deletion attenuates atherosclerotic lesion formation and the development of hepatic steatosis. [19] [20] [21] Although suggestive of a role for GSK3α/β in atherosclerosis, the homolog-and tissue-specific functions of GSK3α and GSK3β, as well as the mechanism by which GSK3α/β regulates atherosclerosis, are not known.
We have developed hepatocyte and myeloid cell-specific GSK3α or GSK3β knockout low-density lipoprotein receptor (LDLR) −/− mice. Our results demonstrate that GSK3α and GSK3β play distinctive homolog-and tissue-specific roles during atherogenesis. Specifically, myeloid GSK3α, but not GSK3β, deletion promotes an M2 macrophage phenotype and attenuates high-fat diet (HFD)-induced atherosclerosis.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Mice
The Cre-loxP system was used to specifically ablate GSK3α or GSK3β expression in myeloid or hepatic cells of LDLR −/− mice. To generate mice lacking GSK3α or GSK3β in hepatic cells, LDLR −/− mice were crossed with GSK3α-floxed 22 or GSK3β-floxed 23 ). All mice have a C57Bl/6 genetic background (>99.9%). Genotypes were determined by polymerase chain reaction ( Figure IA in the online-only Data Supplement). All mice were fed a HFD (21% milk fat, 0.2% cholesterol, Harlan Teklad, TD97363) for 10 weeks beginning at 5 weeks. GSK3α −/− mice were used for bone marrow transplantation experiments. 16, 19 Briefly, 5-week-old recipient mice were irradiated and then injected with bone marrow (3×10 6 cells) from donor mice. Recipient mice were then fed a HFD for 10 weeks. All mice had unlimited access to food and water and were maintained on a 12-hour light/dark cycle. All animal experiments were conducted with approval of the McMaster University Animal Research Ethics Board.
Results

Hepatic or Myeloid Cell-Specific GSK3α or β Knockout LDLR −/− Mice Are Viable and Develop Normally
Tissue-specific ablation of GSK3α or GSK3β protein expression was confirmed by immunoblot ( Figure 1A ). LLαKO and LLβKO mice have no detectible expression of hepatic GSK3α or GSK3β protein, respectively, but retain GSK3α/β expression in all other tissues, including heart, quadriceps muscle, and brain. Similarly, LMαKO and LMβKO mice have no detectible expression of macrophage GSK3α or GSK3β protein, respectively, but retain GSK3α/β expression in all other tissues. There was no detectable compensation in the expression of the retained homolog when GSK3α or GSK3β was deleted in hepatic or myeloid cells ( Figure 1B ). All mice are viable, fertile, born at expected Mendelian frequencies, and do not display any overt phenotype. All mouse strains have similar body weights to littermate controls (Tables 1 and 2 ; Figure IB in the online-only Data Supplement).
Hepatic GSK3α or GSK3β Deletion Does Not Affect Atherosclerosis
To determine the effect of hepatic GSK3α or GSK3β deletion on atherosclerosis at the aortic root, female LLαKO and LLβKO mice and Lαfl/fl and Lβfl/fl controls were placed on a HFD (21% milk fat and 0.2% cholesterol) for 10 weeks beginning at 5 weeks. Metabolic parameters, including plasma cholesterol, plasma triglyceride, blood glucose, liver weight, and adipose weight, were not altered in HFD-fed LLαKO and LLβKO mice relative to controls (Table 1) . Analysis of atherosclerotic lesions at the aortic root revealed no change in lesion area, lesion volume, or necrotic core volume in LLαKO and LLβKO mice relative to Lαfl/fl and Lβfl/fl controls (Figure IIA-IIC and IIF-III in the online-only Data Supplement). Hepatic GSK3α or GSK3β deletion did not affect plasma interleukin (IL)-6, tumor necrosis factor-α, or IL-10 levels ( Figure IIE and IIJ) . Similar effects were observed in male mice ( Figure III in the online-only Data Supplement). These data suggest that modulation of hepatic GSK3α or β activity does not affect atherosclerosis.
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Hepatic GSK3α or GSK3β Deletion Does Not Affect Hepatic Lipid Content
GSK3α/β signaling plays an important role in the regulation of cellular lipid metabolism. 12, 19, 20, 24 However, the homolog-specific functions of GSK3α and GSK3β in hepatic lipid metabolism have not been determined. Therefore, we analyzed lipid metabolism in the liver of HFD-fed LLαKO and LLβKO mice. 
Myeloid GSK3α Deletion Attenuates Atherosclerosis
To determine the role of GSK3α in myeloid cells during atherogenesis, LMαKO and Lαfl/fl control mice were placed on a HFD. After 10 weeks of HFD feeding, myeloid cell ablation of GSK3α did not significantly alter plasma cholesterol, triglyceride, or glucose concentrations or affect liver or adipose weight (Table 2) GSK3α/β plays a role in the regulation of inflammatory cytokine expression. 19, 25, 26 To investigate this further, we analyzed the plasma cytokine profile in LMαKO mice. After 10 weeks of HFD, LMαKO mice displayed reduced plasma levels of the proinflammatory cytokines IL-6 and tumor necrosis factor-α, and increased plasma levels of the anti-inflammatory cytokine IL-10 ( Figure 3E ). Similar effects were observed in male LMαKO mice (Figure VIIA-VIIC in the online-only Data Supplement).
Whole-body GSK3α deficiency attenuates atherosclerosis in HFD-fed LDLR −/− mice. 19 To investigate the role of myeloid GSK3α in an alternate model of experimental atherosclerosis, LDLR −/− mice were irradiated and transplanted with LDLR −/− GSK3α −/− or LDLR −/− GSK3α +/+ (control) bone marrow. We found that atherosclerosis was attenuated in 
Myeloid GSK3β Deletion Does Not Alter Atherosclerosis
Myeloid GSK3β deletion did not affect plasma cholesterol, triglyceride, or glucose concentration or alter liver or adipose weight (Table 2) 
GSK3α Deletion Promotes M2 Macrophage Polarization
We examined the possible effects of myeloid GSK3α or GSK3β deficiency on monocyte subsets and macrophage phenotype. We first established that myeloid GSK3α or GSK3β deletion does not alter the number of monocytes in whole blood ( Figure IXA in the online-only Data Supplement). Next, Cd115 + Cd11b + monocytes were gated from whole blood of LMαKO, LMβKO, and control mice; Ly6C expression was determined by flow cytometry. Myeloid deletion of GSK3α or GSK3β did not affect the proportion of Ly6C hi , Ly6C int , or Ly6C lo monocyte populations, suggesting that GSK3α/β does not play a role in the differentiation of these monocyte subsets ( Figure IXB in the online-only Data Supplement).
We next investigated the effect of GSK3α or GSK3β deletion on macrophage polarization within atherosclerotic lesions. Analysis of the entire length of the lesion revealed that Mac3 + macrophages from lesions of LMαKO mice displayed decreased expression of the M1 markers, fatty acid binding protein-4, and CD36 and increased expression of the M2 markers Arginasae (Arg)-1 and peroxisome proliferator-activated receptor γ coactivator (Pgc)-1 ( Figure 5 ). 27 Mac3 + cells within the atherosclerotic lesions of LMβKO mice showed no change in the expression of M1 markers and an increase in the expression of the M2 marker Pgc1, but not of the Arg1 ( Figure 5 ).
To further investigate the role of GSK3α and GSK3β in macrophage polarization, bone marrow was isolated from LMαKO, LMβKO, and control mice. Cells were exposed to 10 ng/mL macrophage colony stimulating factor for 5 days to induce differentiation into unstimulated, M0, bone marrowderived macrophages. Bone marrow-derived macrophages were then polarized into classical M1 macrophages by exposure to 10 ng/mL lipopolysaccharide for 6 hours or polarized into alternative M2 macrophages by exposure to 10-ng/mL IL-4 for 24 hours. Total RNA was isolated from the cells, and the transcript expression of genes suggestive of M1 or M2 polarization was determined. GSK3α-deficient macrophages treated with lipopolysaccharide had significantly decreased expression of the M1 markers tumor necrosis factor-α, IL-6, CD36, fatty acid binding protein-4, IL-1β, and IL-12 ( Figure 6A ). 27 Similarly treated GSK3β-deficient macrophages had decreased expression of fatty acid binding protein-4, IL-1β, and IL-12 ( Figure 6A ). GSK3α-deficient macrophages had elevated levels of the M2 markers IL-10, Arg1, Fizz1, Ym1, Mgl-2, and Pgc1β, when exposed to IL-4 ( Figure 6B) . 27 Similarly treated GSK3β-deficient macrophages had elevated expression of Arg1 only, relative to controls ( Figure 6B) .
Signal transducer and activator of transcription (STAT) proteins regulate transcription of the M1 and M2 gene programs (reviewed by Biswas and Mantovani 28 ). In M1 polarized cells, STAT1 becomes phosphorylated and promotes the transcription of the M1 gene program. [29] [30] [31] As a negative feedback mechanism, STAT3 is also phosphorylated in M1 cells and suppresses P-STAT1 activity by forming STAT3:STAT1 heterodimers. [32] [33] [34] [35] Exposing macrophages to IL-4 results in the phosphorylation of STAT6 and the transcription of the M2 gene program. [36] [37] [38] We investigated the effect of GSK3α or GSK3β deletion on STAT phosphorylation/activation. Exposure of bone marrow-derived macrophages to lipopolysaccharide Figure 6C and 6D) . GSK3α or GSK3β deletion did not alter P-Tyr701-STAT1 levels ( Figure 6C and 6D ). GSK3α deletion, but not GSK3β deletion, promoted P-Tyr705-STAT3 in lipopolysaccharide-treated macrophages ( Figure 6C and 6D). Polarization of bone marrow-derived macrophages into M2 macrophages by IL-4 induced STAT6 phosphorylation and deletion of GSK3α, but not of GSK3β, promoted P-Tyr641-STAT6 relative to controls ( Figure 6C and 6D) . Together, these data suggest that myeloid GSK3α deficiency enhances the M2 macrophage phenotype through increased STAT3 and STAT6 phosphorylation and activation.
Discussion
Here, we present the first evidence for tissue-and homolog-specific functions of GSK3α/β in atherosclerosis. Myeloid GSK3α deletion, but not GSK3β deletion, attenuated atherosclerosis in HFD LDLR −/− mice and promoted an anti-inflammatory cytokine profile. Bone marrow from LDLR −/− (GSK3α +/+ ) mice enhanced atherosclerotic lesion formation when transplanted into LDLR −/− GSK3α −/− mice. Moreover, macrophage GSK3α deletion suppressed M1 polarization and promoted M2 polarization in both cultured macrophages and macrophages within the atherosclerotic lesion. Hepatic deletion of GSK3α or GSK3β did not alter liver lipid levels, plasma lipid profiles or atherosclerosis at the aortic root. Together, these data highlight a critical and specific role for myeloid GSK3α in atherosclerosis progression and macrophage phenotype.
Signaling through GSK3α/β is important in the regulation of liver glucose and lipid metabolism. Systemic inhibition of GSK3α/β improves glucose tolerance and insulin sensitivity in multiple rodent models of diabetes. 39, 40 We have previously shown that systemic inhibition of GSK3α/β or whole-body deletion of GSK3α attenuates hepatic steatosis. 19, 20 Herein, we present data that hepatocyte or myeloid cell-specific deletion of GSK3α or β does not alter plasma or liver lipid levels. Similarly, hepatocyte-specific deletion of GSK3α or GSK3β does not alter glucose or insulin metabolism, tolerance, or signaling. 22, 23 These observations may be explained by the depletion of Kupffer cells attenuates hepatic steatosis and improves insulin sensitivity. [41] [42] [43] Together, these results suggest that functional GSK3α/β signaling in multiple cell types coordinate glucose, insulin, and lipid metabolism in the liver.
Before this study, investigations into the role of GSK3α/β in animal models of atherosclerosis used nonspecific inhibitors or whole-body genetic deletion. [19] [20] [21] These studies were unable to differentiate whether GSK3α/β's role in atherosclerosis was because of alterations in peripheral tissue, such as the liver or adipose, or local alterations within the vessel wall. In this report, we clearly show that GSK3α plays a local role in myeloid cells within the aortic wall during atherosclerosis development. In support of our results from the LMαKO mice, we observe that transplantation of LDLR −/− (GSK3α +/+ ) bone marrow into LDLR −/− GSK3α −/− mice restores atherosclerotic lesion formation. This is a critical observation because LDLR −/− GSK3α −/− mice transplanted with LDLR −/− bone marrow lack GSK3α expression in other cell types important to atherosclerosis progression, including endothelial cells and smooth muscle cells, and further suggests that GSK3α's function in atherosclerosis is myeloid cell specific. However, as in liver pathology, cross talk between cell types within the lesion is important during atherosclerosis development. 44 Our observations of reduced collagen deposition, fibrous cap thickness, and smooth muscle cell content in the lesions of LMαKO mice, suggestive of less complex and less advanced lesions, are consistent with this hypothesis.
Recent studies have implicated a role for GSK3α/β signaling in macrophages function. 12, 19, 25, 26 We have extended these findings and present the first evidence suggesting that GSK3α regulates macrophage, but not monocyte, polarization. Although deletion of GSK3α does not affect Ly6C hi/int/lo monocyte populations, it does shift macrophage polarization toward an M2 phenotype and away from an M1 phenotype. This shift along the macrophage spectrum toward an M2 phenotype may explain the anti-inflammatory cytokine profile and attenuated atherosclerosis observed in LMαKO mice. Indeed, deletion of STAT1, a key promoter of M1 genes, attenuates atherosclerosis, whereas IL-13 deletion inhibits M2 polarization and promotes atherosclerosis. [6] [7] [8] Moreover, during regression of atherosclerotic lesions macrophages switch from an M1 phenotype to an M2 phenotype. 45, 46 Mhem and Mox macrophages also play functional roles in atherosclerosis progression; however, their contributions are less well characterized.
Together, our data are consistent with a model in which proatherogenic stimuli signal through macrophage GSK3α to promote lesion growth and development. The factors that lie directly upstream of GSK3α have yet to be identified. Our previous results have suggested that endoplasmic reticulum stress activates GSK3α/β via induction of the PERK pathway. 12, 20 Recently, the serine/threonine kinase AKT has been shown to modulate atherosclerosis and macrophage polarization. 47 This is intriguing because AKT is activated by endoplasmic reticulum stress and is a known regulator of GSK3α/β. The factors lying directly downstream of GSK3α are also not known. Herein, we present evidence for STAT3 and STAT6 being targets of GSK3α signaling. Increased P-STAT3 in GSK3α-null M1 cells and increased P-STAT6 in GSK3α-null M2 cells underscore the role of GSK3α activation in shifting macrophages toward the M1 phenotype and promoting atherosclerosis. Furthermore, GSK3α/β is an established regulator of nuclear factor-κB, which also influences macrophage phenotype. 17, 48 The identification of the factors directly upstream and downstream of GSK3α in JAK/ STAT signaling, and their effect on M1 and M2 polarization, is a critical next step.
The therapeutic potential of small molecule inhibitors of GSK3α/β has been limited by our lack of understanding of its homolog-specific functions. Our results suggest that specific targeting of GSK3α may have many clinical advantages as an antiatherogenic therapy. First, modulating specific macrophage subpopulations in the vessel wall may alter local macrophage behavior while retaining systemic functions. Furthermore, the inhibition of GSK3α specifically would be predicted to have fewer side effects because GSK3β signaling would be maintained.
In summary, we present the first evidence for tissue-and homolog-specific functions of GSK3α/β in atherosclerosis. We demonstrate that myeloid cell GSK3α signaling regulates atherosclerosis development and macrophage polarization. -/-mice were a generous gifts from Dr. Bradley Doble (McMaster University) and Dr. Jim Woodgett (University of Toronto). [1] [2] [3] [4] All mice were backcrossed >10 times onto a C57Bl6 background. Genotype was determined by PCR (Supplementary Figure 1) . Tissue specific GSK3α or GSK3β knockout LDLR -/-mice were placed on a high fat diet (HFD) containing 21% milk fat, 0.2% cholesterol (42% kcal from fat)(Harlan Teklad, TD97363) at 5 weeks of age and sacrificed at 15 weeks of age. For bone marrow transplantation experiments, 5 weeks old recipient mice were irradiated with 12Gy of γ-irradiation from a 137 C source using a Gammacel 3000 small animal irradiator. Irradiated mice received bone marrow (3X10 6 cells) injected by i.v. and were left to recover for 4 weeks before being switched to a HFD for 10 weeks (from 9 to 19 weeks of age). All mice had unlimited access to food and water. Body weights were monitored and fasted blood glucose and lipid levels were quantified as previously described. 5 Pooled plasma from at least 5 animals of each group was fractioned using fast performance liquid chromatography with the FRAC-950 FPLC (Amersham Pharmacia Biotech) and cholesterol concentration was measured using the infinity cholesterol reagent (Thermo Scientific). Plasma IL-6, TNFα and IL-10 was quantified by ELISA (eBioScience). Monocyte concentration in whole blood was determined using a Hemavet 950 Multi Species Hematology System (Drew Scientific). Plasma and tissue cholesterol and triglyceride levels were determined using infinity reagent (Thermo Scientific).
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Tissue collections and analysis
After 10 weeks of HFD feeding mice were anesthetized (isoflourane) and harvested at 15 weeks (tissue specific knockout mice) or 19 weeks (bone marrow transplant mice) of age. Vasculature was flushed with saline and perfusion fixed with 10% neutral buffer formalin. Hearts, aortas and liver were collected for further analysis. Hearts and aortas were imbedded in paraffin and serial 5μm sections of the aortic root were collected. Sections were stained with Harris hematoxylin and eosin (Sigma) and Masons Trichrome (Sigma). On a separate subset of mice, hearts, aortas and liver were imbedded in optical cutting temperature (OCT) compound (Tissue-Tek) and frozen. OCT imbedded frozen tissue was serial sectioned at 10μm and stained with Oil Red O and Mayer's Hematoxylin (Sigma). Images were collected using a Leitz LABORLUX S microscope connected to a DP71 Olympus camera and lesion area was quantified using Image J 1.43M software as previously described. 6 Briefly, for atherosclerotic lesion area, volume and necrotic core volume paraffin imbedded sections stained with H&E were used. Sections 60μm apart spanning the entire length of the lesion were used. Fibrous cap thickness was determined throughout the length of the lesion using ImageJ software. Average fibrous cap thickness is
